ScinoPharm Taiwan Ltd (台灣神隆), which makes active pharmaceutical ingredients (APIs), said it expects adverse market conditions to continue to affect its business this year.
The company’s core business of exporting generic drugs has been hit by falling prices as a series of mergers and acquisitions (M&A) raised the bargaining power of US-based drug distributors through joint procurements, it said.
The company also said it expects continued headwinds from a stronger New Taiwan dollar, after sales last year declined 6 percent due to exchange-rate fluctuations.
ScinoPharm on Friday reported that net income last year fell 36 percent annually to NT$422 million (US$14.4 million), with sales dipping 13 percent to NT$3.52 billion.
Earnings per share were NT$0.53, it said.
The company’s clients have trimmed their orders for Paclitaxel, a chemotherapy for ovarian and breast cancer, amid an inventory correction, while shipments of other major generic drugs were delayed due to the replacement and integration of product lines and factories in the wake of M&As among clients, ScinoPharm said.
However, the company said that manufacturing contracts for newly approved antibiotics Baxdela and Vibativ helped offset some of the lost sales in generic drugs.
ScinoPharm said that its partnership with Baxter International Inc has begun to bear fruit as it expands into the generic oncology injectibles market.
The partnership with the US-based Baxter enables the companies to jointly develop formulations while sharing the risks and profits, ScinoPharm said.
Royalties from its anticoagulant Fondaparinux last year increased significantly from a year earlier, it added.
As for the operations of its Changshu plant in China’s Jiangsu Province, ScinoPharm said that the increase in the plant’s revenue contribution has not been as fast as expected due to the rapidly changing environmental safety and health-related laws in China.
The company will continue with its strategy of integrating niche APIs and venturing into formulation, chief executive officer Fred Chen (陳勇發) said in a statement.
In terms of product selection, the company aims to prioritize the distribution of vertically integrated injectables, including small molecule injections and peptide APIs, Chen said.
Regarding the contract research and manufacturing business, the company is seeking new projects in targeted therapy and orphan drugs that have shorter development cycles, he said.
Taichung reported the steepest fall in completed home prices among the six special municipalities in the first quarter of this year, data compiled by Taiwan Realty Co (台灣房屋) showed yesterday. From January through last month, the average transaction price for completed homes in Taichung fell 8 percent from a year earlier to NT$299,000 (US$9,483) per ping (3.3m²), said Taiwan Realty, which compiled the data based on the government’s price registration platform. The decline could be attributed to many home buyers choosing relatively affordable used homes to live in themselves, instead of newly built homes in the city’s prime property market, Taiwan Realty
The government yesterday approved applications by Alphabet Inc’s Google to invest NT$27.08 billion (US$859.98 million) in Taiwan, the Ministry of Economic Affairs said in a statement. The Department of Investment Review approved two investments proposed by Google, with much of the funds to be used for data processing and electronic information supply services, as well as inventory procurement businesses in the semiconductor field, the ministry said. It marks the second consecutive year that Google has applied to increase its investment in Taiwan. Google plans to infuse NT$25.34 billion into Charter Investments Ltd (特許投資顧問) through its Singapore-based subsidiary Fructan Holdings Singapore Pte Ltd, and
JET JUICE: The war on Iran’s secondary effects have seen fuel prices skyrocket, knocking flight schedules down to earth in return as airlines struggle with costs Airline passengers should brace for more irritation in the next few months as carriers worldwide cancel flights and ground planes to cope with stratospheric increases in jet-fuel prices. Dutch flag carrier KLM is the latest company to cut its schedule, saying on Thursday that it would scrap 80 return flights at Amsterdam’s Schiphol Airport in the coming month. That puts it in the same league as United Airlines Holdings Inc, Deutsche Lufthansa AG and Cathay Pacific Airways Ltd, which have all pruned itineraries to mitigate costs. Global capacity for next month has been reduced by about 3 percentage points, with all
Micron Technology Inc is a driving force pushing the US Congress to pass legislation that would put new export restrictions on equipment its Chinese competitors use to make their chips, according to people familiar with the matter. A US House of Representatives panel yesterday was to vote on the “MATCH Act,” a bill designed to close gaps in restrictions on chipmaking equipment. It would also pressure foreign companies that sell equipment to Chinese chipmaking facilities to align with export curbs on US companies like Lam Research Corp and Applied Materials Inc. The bill targets facilities operated by China’s ChangXin Memory Technologies Inc